1. Home
  2. AKBA vs ARQ Comparison

AKBA vs ARQ Comparison

Compare AKBA & ARQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • ARQ
  • Stock Information
  • Founded
  • AKBA 2007
  • ARQ 1996
  • Country
  • AKBA United States
  • ARQ United States
  • Employees
  • AKBA N/A
  • ARQ N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • ARQ
  • Sector
  • AKBA Health Care
  • ARQ
  • Exchange
  • AKBA Nasdaq
  • ARQ NYSE
  • Market Cap
  • AKBA 336.2M
  • ARQ 311.5M
  • IPO Year
  • AKBA 2014
  • ARQ N/A
  • Fundamental
  • Price
  • AKBA $2.37
  • ARQ $6.84
  • Analyst Decision
  • AKBA Strong Buy
  • ARQ Strong Buy
  • Analyst Count
  • AKBA 1
  • ARQ 1
  • Target Price
  • AKBA $7.50
  • ARQ $10.00
  • AVG Volume (30 Days)
  • AKBA 2.4M
  • ARQ 342.1K
  • Earning Date
  • AKBA 03-13-2025
  • ARQ 03-12-2025
  • Dividend Yield
  • AKBA N/A
  • ARQ N/A
  • EPS Growth
  • AKBA N/A
  • ARQ N/A
  • EPS
  • AKBA N/A
  • ARQ N/A
  • Revenue
  • AKBA $169,879,000.00
  • ARQ $110,023,000.00
  • Revenue This Year
  • AKBA N/A
  • ARQ $13.02
  • Revenue Next Year
  • AKBA $30.85
  • ARQ $30.37
  • P/E Ratio
  • AKBA N/A
  • ARQ N/A
  • Revenue Growth
  • AKBA N/A
  • ARQ 16.44
  • 52 Week Low
  • AKBA $0.80
  • ARQ $2.70
  • 52 Week High
  • AKBA $2.48
  • ARQ $8.26
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 75.15
  • ARQ 50.12
  • Support Level
  • AKBA $1.72
  • ARQ $6.96
  • Resistance Level
  • AKBA $2.00
  • ARQ $6.68
  • Average True Range (ATR)
  • AKBA 0.11
  • ARQ 0.37
  • MACD
  • AKBA 0.04
  • ARQ -0.03
  • Stochastic Oscillator
  • AKBA 100.00
  • ARQ 48.37

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About ARQ ARQ INC

Arq Inc is an environmental technology company principally engaged in the sale of consumable air, water, and soil treatment solutions including activated carbon (AC) and chemical technologies. The company manufactures and sells activated carbon and other chemicals used to capture and remove contaminants for the coal-fired power generation, industrial, municipal water and air, water and soil treatment and remediation markets. Some of the products in its portfolio are Powdered Activated Carbon, Granular Activated Carbon, and Colloidal Carbon Product among others.

Share on Social Networks: